AFP and hepatocellular carcinoma: In 2023, Fan et al. advanced this paradigm by introducing the aMAP-2 and aMAP-2 Plus models, which incorporate longitudinal clinical data to dynamically track changes in aMAP scores and AFP levels, thereby capturing the temporal evolution of HCC risk [102].